3-(4-(1H-indazol-4-ylamino)pyrimidin-2-ylamino)benzenesulfonamide

ID: ALA398894

PubChem CID: 25138049

Max Phase: Preclinical

Molecular Formula: C17H15N7O2S

Molecular Weight: 381.42

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  NS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1

Standard InChI:  InChI=1S/C17H15N7O2S/c18-27(25,26)12-4-1-3-11(9-12)21-17-19-8-7-16(23-17)22-14-5-2-6-15-13(14)10-20-24-15/h1-10H,(H,20,24)(H2,18,25,26)(H2,19,21,22,23)

Standard InChI Key:  KVSWEQSTPCJTSJ-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
    1.6369   -2.8053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6351   -3.6346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3500   -4.0479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0677   -3.6337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0631   -2.7993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3470   -2.3922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7749   -2.3867    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4919   -2.7948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4916   -3.6207    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2070   -4.0291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9206   -3.6116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9158   -2.7838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1989   -2.3775    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2114   -4.8541    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9283   -5.2631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9270   -6.0903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6424   -6.4986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3493   -6.0793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6311   -4.8470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3496   -5.2549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9606   -4.6988    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6167   -3.9515    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7966   -4.0417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3496   -4.8724    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.3445   -5.6969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1741   -4.8751    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.5252   -4.8697    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
 10 14  1  0
  5  7  1  0
 14 15  1  0
  3  4  2  0
 15 16  2  0
  7  8  1  0
 16 17  1  0
 17 18  2  0
 19 15  1  0
 20 18  1  0
 19 20  2  0
  8  9  2  0
  4  5  1  0
  9 10  1  0
  2  3  1  0
 10 11  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 19  1  0
  5  6  2  0
 11 12  1  0
  6  1  1  0
 12 13  2  0
  3 24  1  0
 24 25  1  0
 13  8  1  0
 24 26  2  0
  1  2  2  0
 24 27  2  0
M  END

Associated Targets(non-human)

Lck Tyrosine-protein kinase LCK (196 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 381.42Molecular Weight (Monoisotopic): 381.1008AlogP: 2.49#Rotatable Bonds: 5
Polar Surface Area: 138.68Molecular Species: NEUTRALHBA: 7HBD: 4
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 5#RO5 Violations (Lipinski):
CX Acidic pKa: 10.24CX Basic pKa: 4.28CX LogP: 2.13CX LogD: 2.13
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.42Np Likeness Score: -2.09

References

1. Bamborough P, Angell RM, Bhamra I, Brown D, Bull J, Christopher JA, Cooper AW, Fazal LH, Giordano I, Hind L, Patel VK, Ranshaw LE, Sims MJ, Skone PA, Smith KJ, Vickerstaff E, Washington M..  (2007)  N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.,  17  (15): [PMID:17600705] [10.1016/j.bmcl.2007.04.029]
2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]